Wnt pathway in osteosarcoma, from oncogenic to therapeutic

Journal of Cellular Biochemistry

Volumn 115, Issue 4, 2014, Pages 625-631

  Cai, Yu ^a   Cai, Tiange ^b   Chen, Yan ^c  

^a JINAN UNIVERSITY   (China)

^b LIAONING UNIVERSITY   (China)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

BETA CATENIN; OSTEOSARCOMA; Wnt

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CADHERIN; CELECOXIB; CURCUMIN; DIHYDROARTEMISININ; DOXORUBICIN; FRIZZLED PROTEIN; MONOCLONAL ANTIBODY; PKF 118 310; UNCLASSIFIED DRUG; UVOMORULIN; WNT INHIBITORY FACTOR 1; WNT PROTEIN; WNT1 PROTEIN; WNT10B PROTEIN; WNT2 PROTEIN; WNT3 PROTEIN; WNT3A PROTEIN; WNT4 PROTEIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL MOTION; CELL POLARITY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NONHUMAN; OSTEOBLAST; OSTEOCHONDROMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY;

BETA-CATENIN; OSTEOSARCOMA; WNT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BETA CATENIN; BONE NEOPLASMS; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; OSTEOSARCOMA; REPRESSOR PROTEINS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84892923802     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24708     Document Type: Article

References (50)

1. Akiyama T,. 2000. Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 11: 273-282.
2. Arvanitis C, Bendapudi PK, Tseng JR, Gambhir SS, Felsher DW,. 2008. (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. Cancer Biol Ther 7: 1947-1951.
3. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA,. 2001. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 3: 683-686.
4. Behrens J,. 2000. Cross-regulation of the Wnt signalling pathway: A role of MAP kinases. J Cell Sci 113 (Pt 6): 911-919.
5. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP,. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 1513-1521.
6. Chen K, Fallen S, Abaan HO, Hayran M, Gonzalez C, Wodajo F, MacDonald T, Toretsky JA, Uren A,. 2008. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer 51: 349-355.
7. Chen Y, Alman BA,. 2009. Wnt pathway, an essential role in bone regeneration. J Cell Biochem 106: 353-362.
8. Chen Y, Shi HY, Stock SR, Stern PH, Zhang M,. 2011. Regulation of breast cancer-induced bone lesions by beta-catenin protein signaling. J Biol Chem 286: 42575-42584.
9. Chen Y, Whetstone HC, Lin AC, Nadesan P, Wei Q, Poon R, Alman BA,. 2007. Beta-catenin signaling plays a disparate role in different phases of fracture repair: Implications for therapy to improve bone healing. PLoS Med 4: e249.
10. Eastman Q, Grosschedl R,. 1999. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr Opin Cell Biol 11: 233-240.
11. Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M, Tamada K, Oneyama C, Okada M, Takumi T, Nishita M, Minami Y,. 2009. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28: 3197-3208.
12. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML,. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513-523.
13. Gordon MD, Nusse R,. 2006. Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281: 22429-22433.
14. Guo Y, Zi X, Koontz Z, Kim A, Xie J, Gorlick R, Holcombe RF, Hoang BH,. 2007. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 25: 964-971.
15. Habas R, Dawid IB,. 2005. Dishevelled and Wnt signaling: Is the nucleus the final frontier ? J Biol 4: 2.
16. Hartikka H, Makitie O, Mannikko M, Doria AS, Daneman A, Cole WG, Ala-Kokko L, Sochett EB,. 2005. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 20: 783-789.
17. Hartmann C, Tabin CJ,. 2000. Dual roles of Wnt signaling during chondrogenesis in the chicken limb. Development 127: 3141-3159.
18. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L, Feng T, King D, Cheng H, Breyer B, Peabody T, Simon MA, Montag AG, He TC,. 2002. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102: 338-342.
19. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM,. 2004. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6: 7-14.
20. Hoang BH,. 2012. Wnt, osteosarcoma, and future therapy. J Am Acad Orthop Surg 20: 58-59.
21. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA, Gorlick R,. 2004a. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109: 106-111.
22. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA, Gorlick R,. 2004b. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 64: 2734-2739.
23. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K,. 2003. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 20: 525-529.
24. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW,. 2002. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102-104.
25. Ji Y, Zhang YC, Pei LB, Shi LL, Yan JL, Ma XH,. 2011. Anti-tumor effects of dihydroartemisinin on human osteosarcoma. Mol Cell Biochem 351: 99-108.
26. Kansara M, Thomas DM,. 2007. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 26: 1-18.
27. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM,. 2009. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119: 837-851.
28. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA II, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L,. 2002. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157: 303-314.
29. Kawano Y, Kypta R,. 2003. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116: 2627-2634.
30. Kohn AD, Moon RT,. 2005. Wnt and calcium signaling: Beta-catenin- independent pathways. Cell Calcium 38: 439-446.
31. Lin CH, Guo Y, Ghaffar S, McQueen P, Pourmorady J, Christ A, Rooney K, Ji T, Eskander R, Zi X, Hoang BH,. 2013. Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma 2013: 147541.
32. Liu Y, Wang W, Xu J, Li L, Dong Q, Shi Q, Zuo G, Zhou L, Weng Y, Tang M, He T, Luo J,. 2013. Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/beta-catenin signaling. Oncol Rep 30: 1723-1730.
33. Lu BJ, Wang YQ, Wei XJ, Rong LQ, Wei D, Yan CM, Wang DJ, Sun JY,. 2012. Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma. Mol Med Rep 5: 1033-1036.
34. Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs JJ, Gitelis S, O'Keefe RJ, Konttinen YT, Yin G, Li TF,. 2013. Inhibition of the Wnt-beta-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun 431: 274-279.
35. McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X, Hoang BH,. 2011. The Wnt signaling pathway: Implications for therapy in osteosarcoma. Expert Rev Anticancer Ther 11: 1223-1232.
36. Mikami I, You L, He B, Xu Z, Batra S, Lee AY, Mazieres J, Reguart N, Uematsu K, Koizumi K, Jablons DM,. 2005. Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC Cancer 5: 53.
37. Mikels AJ, Nusse R,. 2006. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 4: e115.
38. Modder UI, Oursler MJ, Khosla S, Monroe DG,. 2011. Wnt10b activates the Wnt, notch, and NFkappaB pathways in U2OS osteosarcoma cells. J Cell Biochem 112: 1392-1402.
39. Nagao H, Ijiri K, Hirotsu M, Ishidou Y, Yamamoto T, Nagano S, Takizawa T, Nakashima K, Komiya S, Setoguchi T,. 2011. Role of GLI2 in the growth of human osteosarcoma. J Pathol 224: 169-179.
40. Nelson WJ, Nusse R,. 2004. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487.
41. Niehrs C,. 2006. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25: 7469-7481.
42. Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH,. 2010. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther 9: 731-741.
43. Seto ES, Bellen HJ,. 2004. The ins and outs of Wingless signaling. Trends Cell Biol 14: 45-53.
44. Tetsu O, McCormick F,. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
45. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD, Jr., 2003. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494.
46. Tsuji T, Miyazaki M, Sakaguchi M, Inoue Y, Namba M,. 2000. A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem Biophys Res Commun 268: 20-24.
47. Uren A, Wolf V, Sun YF, Azari A, Rubin JS, Toretsky JA,. 2004. Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer 43: 243-249.
48. Wang HY, Malbon CC,. 2003. Wnt signaling, Ca2+, and cyclic GMP: Visualizing Frizzled functions. Science 300: 1529-1530.
49. Xia JJ, Pei LB, Zhuang JP, Ji Y, Xu GP, Zhang ZP, Li N, Yan JL,. 2010. Celecoxib inhibits beta-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res 38: 1294-1304.
50. Zhang C, Zhao Y, Zeng B,. 2012. Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2. Cancer Biomark 12: 155-167.